UY38476A - Inhibidores de arg1 y/o arg2 - Google Patents
Inhibidores de arg1 y/o arg2Info
- Publication number
- UY38476A UY38476A UY0001038476A UY38476A UY38476A UY 38476 A UY38476 A UY 38476A UY 0001038476 A UY0001038476 A UY 0001038476A UY 38476 A UY38476 A UY 38476A UY 38476 A UY38476 A UY 38476A
- Authority
- UY
- Uruguay
- Prior art keywords
- arg2
- arg1
- inhibitors
- compounds
- disclosed
- Prior art date
Links
- 102100021723 Arginase-1 Human genes 0.000 title abstract 3
- 102100030356 Arginase-2, mitochondrial Human genes 0.000 title abstract 3
- 101000752037 Homo sapiens Arginase-1 Proteins 0.000 title abstract 3
- 101000792835 Homo sapiens Arginase-2, mitochondrial Proteins 0.000 title abstract 3
- 101000800287 Homo sapiens Tubulointerstitial nephritis antigen-like Proteins 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se dan a conocer compuestos que son inhibidores de al menos uno de ARG1 y ARG2, y composiciones que contienen los compuestos, así como métodos para sintetizar los compuestos. También se da a conocer en la presente memoria el uso de dichos compuestos para el tratamiento de una amplia variedad de enfermedades, trastornos, y afecciones, incluidos los trastornos relacionados con el cáncer y el sistema inmunitario que son mediados, al menos en parte, por ARG1 y ARG2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862768284P | 2018-11-16 | 2018-11-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY38476A true UY38476A (es) | 2020-06-30 |
Family
ID=70731928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001038476A UY38476A (es) | 2018-11-16 | 2019-11-15 | Inhibidores de arg1 y/o arg2 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220016143A1 (es) |
| EP (1) | EP3880685A4 (es) |
| JP (1) | JP7461350B2 (es) |
| KR (1) | KR20210108954A (es) |
| CN (1) | CN113382998A (es) |
| AR (1) | AR117102A1 (es) |
| AU (1) | AU2019379808C1 (es) |
| CA (1) | CA3120196A1 (es) |
| TW (1) | TWI828800B (es) |
| UY (1) | UY38476A (es) |
| WO (1) | WO2020102646A2 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022011534A (es) | 2020-03-19 | 2022-10-13 | Arcus Biosciences Inc | Compuestos de tetralina y tetrahidroquinolina como inhibidores de hif-2alfa. |
| JP2023528036A (ja) | 2020-06-02 | 2023-07-03 | アーカス バイオサイエンシズ インコーポレイティド | Ｔｉｇｉｔに対する抗体 |
| US11649261B2 (en) | 2020-06-17 | 2023-05-16 | Arcus Biosciences, Inc. | Crystalline forms of a CD73 inhibitor and uses thereof |
| TW202228720A (zh) | 2020-12-22 | 2022-08-01 | 波蘭商昂科艾倫迪治療法股份公司 | 精胺酸酶抑制劑及其使用方法 |
| TW202313602A (zh) | 2021-05-21 | 2023-04-01 | 美商阿克思生物科學有限公司 | Axl化合物 |
| CN117337288A (zh) | 2021-05-21 | 2024-01-02 | 艾库斯生物科学有限公司 | Axl抑制剂化合物 |
| US20230159466A1 (en) | 2021-10-29 | 2023-05-25 | Arcus Biosciences, Inc. | Inhibitors of hif-2alpha and methods of use thereof |
| WO2023215719A1 (en) | 2022-05-02 | 2023-11-09 | Arcus Biosciences, Inc. | Anti-tigit antibodies and uses of the same |
| US20240124490A1 (en) | 2022-07-15 | 2024-04-18 | Arcus Biosciences, Inc. | Inhibitors of hpk1 and methods of use thereof |
| WO2024020034A1 (en) | 2022-07-20 | 2024-01-25 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| WO2024059142A1 (en) | 2022-09-14 | 2024-03-21 | Arcus Biosciences, Inc. | Dispersions of etrumadenant |
| WO2024081385A1 (en) | 2022-10-14 | 2024-04-18 | Arcus Biosciences, Inc. | Hpk1 inhibitors and methods of use thereof |
| WO2024086718A1 (en) | 2022-10-20 | 2024-04-25 | Arcus Biosciences, Inc. | Lyophilized formulations of cd73 compounds |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105732767A (zh) * | 2009-09-25 | 2016-07-06 | 夏尔孤儿治疗有限公司 | 新的npr-b激动剂 |
| ES2729936T3 (es) | 2010-04-22 | 2019-11-07 | Mars Inc | Inhibidores de arginasa y sus aplicaciones terapéuticas |
| ES2794006T3 (es) * | 2010-10-26 | 2020-11-17 | Mars Inc | Inhibidores de arginasa como agentes terapéuticos |
| WO2013158262A1 (en) * | 2012-04-18 | 2013-10-24 | Mars, Incorporated | Ring constrained analogs as arginase inhibitors |
| PL410665A1 (pl) | 2014-12-29 | 2016-07-04 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| US10143699B2 (en) * | 2015-06-23 | 2018-12-04 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| EP3490581A4 (en) | 2016-07-26 | 2020-10-14 | Flagship Pioneering Innovations V, Inc. | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC PROCEDURES FOR TREATMENT OF CANCER |
| CN110352063A (zh) * | 2016-11-08 | 2019-10-18 | 卡里塞拉生物科学股份公司 | 精氨酸酶抑制剂组合疗法 |
| EP3810615A4 (en) | 2018-06-20 | 2022-03-30 | Merck Sharp & Dohme Corp. | ARGINASE INHIBITORS AND METHODS OF USE |
-
2019
- 2019-11-15 TW TW108141665A patent/TWI828800B/zh active
- 2019-11-15 JP JP2021526441A patent/JP7461350B2/ja active Active
- 2019-11-15 AR ARP190103373A patent/AR117102A1/es unknown
- 2019-11-15 KR KR1020217018476A patent/KR20210108954A/ko not_active Application Discontinuation
- 2019-11-15 EP EP19884624.8A patent/EP3880685A4/en active Pending
- 2019-11-15 CA CA3120196A patent/CA3120196A1/en active Pending
- 2019-11-15 WO PCT/US2019/061657 patent/WO2020102646A2/en active Application Filing
- 2019-11-15 UY UY0001038476A patent/UY38476A/es unknown
- 2019-11-15 AU AU2019379808A patent/AU2019379808C1/en active Active
- 2019-11-15 CN CN201980089420.2A patent/CN113382998A/zh active Pending
- 2019-11-15 US US17/294,353 patent/US20220016143A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220016143A1 (en) | 2022-01-20 |
| TW202033203A (zh) | 2020-09-16 |
| AR117102A1 (es) | 2021-07-14 |
| WO2020102646A3 (en) | 2020-08-13 |
| TWI828800B (zh) | 2024-01-11 |
| JP7461350B2 (ja) | 2024-04-03 |
| JP2022507474A (ja) | 2022-01-18 |
| CA3120196A1 (en) | 2020-05-22 |
| AU2019379808A1 (en) | 2021-06-24 |
| AU2019379808B2 (en) | 2023-08-03 |
| CN113382998A (zh) | 2021-09-10 |
| WO2020102646A2 (en) | 2020-05-22 |
| KR20210108954A (ko) | 2021-09-03 |
| AU2019379808C1 (en) | 2024-01-25 |
| EP3880685A4 (en) | 2022-07-27 |
| EP3880685A2 (en) | 2021-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY38476A (es) | Inhibidores de arg1 y/o arg2 | |
| CO2020012060A2 (es) | Inhibidores de la arginasa | |
| CO2021005987A2 (es) | Compuestos de anillo fusionado | |
| CO2019007863A2 (es) | Derivados de benzooxazol como inmunomoduladores | |
| PH12021500014A1 (en) | Fused ring compounds | |
| CO2019000386A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| DOP2022000077A (es) | Aminas bicíclicas como inhibidoras de la cdk2 | |
| DOP2022000194A (es) | Compuestos de tetralina y tetrahidroquinolina como inhibidores de hif-2alfa | |
| SV2018005787A (es) | 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas | |
| CO2023015484A2 (es) | Compuesto, composiciones y métodos para el tratamiento de trastornos | |
| BR112018067775A2 (pt) | inibidores de mcl-1 indol substituído | |
| UY37378A (es) | Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus | |
| CO2022001210A2 (es) | Conjugados de il-2 y métodos de uso para tratar enfermedades autoinmunes | |
| DOP2020000100A (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 | |
| CL2023000892A1 (es) | Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional). | |
| BR112019002458A2 (pt) | composições e métodos para tratar câncer com depleção de arginina e agentes imuno-oncológicos | |
| ECSP21003171A (es) | Dinucleótidos cíclicos como agonistas de sting | |
| CL2020001062A1 (es) | Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos. | |
| CL2022003206A1 (es) | Compuestos derivados de quinolona y su uso para el tratamiento del cáncer (div. sol. 202102501) | |
| BR112019008606A2 (pt) | inibidores de interações de mtor-deptor e métodos de uso dos mesmos | |
| UY37316A (es) | Dispersión sólida farmacéutica de un inhibidor de bcl-2, composiciones farmacéuticas de ésta, y usos para el tratamiento de cáncer | |
| CR20190028A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| BR112022005940A2 (pt) | Composto, e, composição farmacêutica | |
| CR20190110A (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 |